Stereochemistry | ACHIRAL |
Molecular Formula | C15H10ClN3O3 |
Molecular Weight | 315.711 |
Optical Activity | NONE |
Defined Stereocenters | 0 / 0 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
[O-][N+](=O)C1=CC2=C(NC(=O)CN=C2C3=C(Cl)C=CC=C3)C=C1
InChI
InChIKey=DGBIGWXXNGSACT-UHFFFAOYSA-N
InChI=1S/C15H10ClN3O3/c16-12-4-2-1-3-10(12)15-11-7-9(19(21)22)5-6-13(11)18-14(20)8-17-15/h1-7H,8H2,(H,18,20)
Clonazepam, a benzodiazepine, is used primarily as an anticonvulsant in the treatment of absence seizures, petit mal variant seizures (Lennox-Gastaut syndrome), akinetic and myoclonic seizures, and nocturnal myoclonus. Klonopin is the brand name for Clonazepam, an anxiolytic and anticonvulsant. The precise mechanism by which clonazepam exerts its antiseizure
and antipanic effects is unknown, although it is believed to be related to its ability to
enhance the activity of gamma aminobutyric acid (GABA), the major inhibitory
neurotransmitter in the central nervous system. Allosteric interactions between central benzodiazepine receptors and gamma-aminobutyric acid (GABA) receptors potentiate the effects of GABA. As GABA is an inhibitory neurotransmitter, this results in increased inhibition of the ascending reticular activating system. Benzodiazepines, in this way, block the cortical and limbic arousal that occurs following stimulation of the reticular pathways.
CNS Activity
Originator
Approval Year
Doses
AEs
Sourcing
PubMed
Patents
Sample Use Guides
Seizure Disorders: Adults: The initial dose for adults with seizure disorders should not
exceed 1.5 mg/day divided into three doses. Dosage may be increased in increments of
0.5 to 1 mg every 3 days until seizures are adequately controlled or until side effects
preclude any further increase. Maintenance dosage must be individualized for each
patient depending upon response. Maximum recommended daily dose is 20 mg. Clonazepam is available as a tablet or an orally disintegrating tablet (wafer). The tablets
should be administered with water by swallowing the tablet whole. The orally
disintegrating tablet should be administered as follows: After opening the pouch, peel
back the foil on the blister. Do not push tablet through foil. Immediately upon opening
the blister, using dry hands, remove the tablet and place it in the mouth. Tablet
disintegration occurs rapidly in saliva so it can be easily swallowed with or without water.
Route of Administration:
Oral